Natera, Inc. $NTRA Shares Purchased by Alliancebernstein L.P.

Key Points

• Alliancebernstein L.P. increased its stake in Natera, Inc. by 3.2%, owning 792,410 shares valued at $112 million as of the latest SEC filing.
• Several institutional investors are showing interest in Natera, with positions being acquired or increased, leading to 99.90% of the company being owned by such investors.
• Natera's stock has an average price target of $194 following recent ratings from various analysts, with one analyst assigning a "Strong Buy" rating and seventeen others a "Buy" rating.

Alliancebernstein L.P. boosted its stake in Natera, Inc. (NASDAQ:NTRA - Free Report) by 3.2% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 792,410 shares of the medical research company's stock after buying an additional 24,348 shares during the period. Alliancebernstein L.P. owned 0.59% of Natera worth $112,055,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in NTRA. LRI Investments LLC acquired a new position in shares of Natera during the fourth quarter valued at $29,000. Bank of Jackson Hole Trust acquired a new position in shares of Natera during the first quarter valued at $29,000. Rakuten Securities Inc. increased its holdings in shares of Natera by 117.8% during the first quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock valued at $31,000 after purchasing an additional 119 shares during the period. TCTC Holdings LLC increased its holdings in shares of Natera by 114.8% during the first quarter. TCTC Holdings LLC now owns 232 shares of the medical research company's stock valued at $33,000 after purchasing an additional 124 shares during the period. Finally, ORG Partners LLC acquired a new position in shares of Natera during the first quarter valued at $32,000. 99.90% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on NTRA shares. Royal Bank Of Canada set a $268.00 price target on Natera and gave the company an "outperform" rating in a report on Tuesday. Barclays reissued an "overweight" rating and set a $210.00 price target (up from $190.00) on shares of Natera in a report on Friday, August 8th. Piper Sandler reissued an "overweight" rating and set a $220.00 price target (up from $210.00) on shares of Natera in a report on Monday, August 11th. Wall Street Zen lowered Natera from a "hold" rating to a "sell" rating in a report on Saturday, May 17th. Finally, UBS Group raised their price target on Natera from $211.00 to $218.00 and gave the company a "buy" rating in a report on Friday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating and seventeen have assigned a Buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $194.00.

Insider Transactions at Natera

In related news, Director Rowan E. Chapman sold 2,750 shares of Natera stock in a transaction dated Thursday, August 28th. The stock was sold at an average price of $166.99, for a total value of $459,222.50. Following the transaction, the director owned 6,015 shares of the company's stock, valued at approximately $1,004,444.85. This trade represents a 31.37% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Michael Burkes Brophy sold 3,045 shares of Natera stock in a transaction dated Tuesday, July 29th. The stock was sold at an average price of $137.40, for a total value of $418,383.00. Following the completion of the transaction, the chief financial officer directly owned 65,430 shares in the company, valued at $8,990,082. This represents a 4.45% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 55,344 shares of company stock worth $8,271,610 in the last three months. Insiders own 5.63% of the company's stock.

Natera Stock Up 0.9%

Shares of NTRA stock opened at $168.02 on Friday. The stock has a 50-day simple moving average of $154.35 and a 200 day simple moving average of $153.91. Natera, Inc. has a fifty-two week low of $110.57 and a fifty-two week high of $183.00. The stock has a market capitalization of $23.06 billion, a P/E ratio of -87.97 and a beta of 1.68.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). The company had revenue of $546.60 million during the quarter, compared to analyst estimates of $476.84 million. Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The company's revenue for the quarter was up 32.2% compared to the same quarter last year. During the same quarter last year, the business earned ($0.30) EPS. Natera has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.